Outcomes of GLP-1 receptor agonist therapy in adults with sickle cell disease and type 2 diabetes: a real-world cohort analysis - PubMed
5 hours ago
- #Type 2 diabetes
- #Sickle cell disease
- #GLP-1 receptor agonist
- GLP-1 receptor agonist therapy in adults with sickle cell disease (SCD) and type 2 diabetes mellitus (T2DM) is associated with a significantly lower risk of major adverse cardiovascular events (MACE), with a hazard ratio (HR) of 0.61 (95% CI 0.49-0.76).
- The therapy also reduces the risk of stroke (HR 0.47, 95% CI 0.23-0.97) and vaso-occlusive crises (VOC) by 36% (HR 0.64, 95% CI 0.45-0.91), indicating vaso-stabilizing effects.
- No significant differences were found between GLP-1 users and non-users in the risks of hypoglycemia (HR 1.10, 95% CI 0.60-1.76) or progression to chronic kidney disease (CKD) (HR 1.26, 95% CI 0.82-1.95), suggesting a favorable safety profile.